Novartis AG ADR (NVS)vsNyxoah (NYXH)
NVS
Novartis AG ADR
$156.15
-1.45%
HEALTHCARE · Cap: $290.96B
NYXH
Nyxoah
$1.40
-0.71%
HEALTHCARE · Cap: $143.10M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 369766% more annual revenue ($56.69B vs $15.33M). NVS leads profitability with a 22.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
NYXH
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-70.9%
Fair Value
$92.73
Current Price
$156.15
$63.42 premium
Intrinsic value data unavailable for NYXH.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 31.8%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Reasonable price relative to book value
Revenue surging 498.9% year-over-year
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.
Bull Case : NYXH
The strongest argument for NYXH centers on Price/Book, Revenue Growth. Revenue growth of 498.9% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : NYXH
The primary concerns for NYXH are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
NVS profiles as a value stock while NYXH is a hypergrowth play — different risk/reward profiles.
NYXH carries more volatility with a beta of 0.96 — expect wider price swings.
NYXH is growing revenue faster at 498.9% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 27/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Nyxoah
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Nyxoah is an innovative medical technology firm dedicated to advancing treatment options for obstructive sleep apnea (OSA) through its proprietary Genio system, which employs minimally invasive hypoglossal nerve stimulation. The company is committed to clinical validation and extensive research to enhance patient outcomes and quality of life for individuals affected by OSA. By prioritizing innovation in the sleep medicine domain and fostering strategic partnerships, Nyxoah is strategically positioned to leverage the growing demand for effective OSA treatments, indicating strong prospects for long-term growth within the healthcare industry.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?